At the time of writing, Allogene Therapeutics Inc [ALLO] stock is trading at $1.18, up 3.51%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ALLO shares have gain 6.31% over the last week, with a monthly amount drifted -23.38%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Allogene Therapeutics Inc [NASDAQ: ALLO] stock has seen the most recent analyst activity on May 14, 2025, when Citizens JMP downgraded its rating to a Mkt Perform. Previously, Citizens JMP upgraded its rating to Mkt Outperform on March 14, 2025, and kept the price target unchanged to $5. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $11 on May 31, 2024. JMP Securities downgraded its rating to a Mkt Perform. Guggenheim downgraded its rating to Neutral for this stock on January 05, 2024. In a note dated December 08, 2023, Citigroup initiated an Buy rating and provided a target price of $7 on this stock.
For the past year, the stock price of Allogene Therapeutics Inc fluctuated between $0.86 and $3.78. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Allogene Therapeutics Inc [NASDAQ: ALLO] shares were valued at $1.18 at the most recent close of the market. An investor can expect a potential return of 2357.63% based on the average ALLO price forecast.
Analyzing the ALLO fundamentals
According to Allogene Therapeutics Inc [NASDAQ:ALLO], the company’s sales were 0.00M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 12222.09%, Pretax Profit Margin comes in at 11449.09%, and Net Profit Margin reading is 11469.23%. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -0.56 and Total Capital is -0.56. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1333 points at the first support level, and at 1.0867 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.2133, and for the 2nd resistance point, it is at 1.2467.
Ratios To Look Out For
It is important to note that Allogene Therapeutics Inc [NASDAQ:ALLO] has a current ratio of 9.71. Also, the Quick Ratio is 9.71, while the Cash Ratio stands at 1.41.
Transactions by insiders
Recent insider trading involved Yoshiyama Annie, SVP, Finance, that happened on Apr 21 ’25 when 9601.0 shares were sold. Officer, Yoshiyama Annie completed a deal on Apr 21 ’25 to buy 9601.0 shares. Meanwhile, President and CEO Chang David D sold 46668.0 shares on Mar 14 ’25.
